Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06493578 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
A Phase 2 study of Non-segmental Vitiligo, sponsored by Vyne Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06493578: Active Phase 2 study of Non-segmental Vitiligo, sponsored by Vyne Therapeutics.
NCT06493578 is a Phase 2 study of Non-segmental Vitiligo that is active but no longer recruiting, run by Vyne Therapeutics. The registered enrollment target is 200 participants, below the 248-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06493578, a Phase 2 study of Non-segmental Vitiligo, is active but no longer recruiting, sponsored by Vyne Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
Primary Outcome
Proportion of subjects who achieve a ≥50% improvement from Baseline in F-VASI score at Week 24.
Conditions Studied
Interventions
- DRUG VYN201 Gel
- DRUG Vehicle Gel
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research, Inc - Fountain Valley
- Center for Dermatology Clinical Research, Inc - Fremont
- Marvel Clinical Research - Huntington Beach
- Northridge Clinical Trials - Northridge
- Palmtree Clinical Research, Inc. - Palm Springs
- Integrative Skin Science and Research - Sacramento
Florida
- Skin Care Research - Boca Raton
- Driven Research LLC - Coral Gables
- Skin Care Research - Hollywood
- International Clinical Research - FL LLC - Sanford
- Metabolic Research Institute, Inc - West Palm Beach
Arizona
- Saguaro Dermatology - Phoenix
- Center for Dermatology and Plastic Surgery/CCT Research - Scottsdale
- Noble Clinical Research - Tucson
Arkansas
- Clinical Trial Institute of Northwest Arkansas, LLC - Fayetteville
- Burke Pharmaceutical Research - Hot Springs
Colorado
- Clarity Dermatology - Castle Rock
- Colorado Medical Research Center - Denver
Alabama
- Cahaba Dermatology & Skin Health Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
What the registry record for NCT06493578 still lists
NCT06493578 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 248-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which VYN201 Gel is the first listed.
NCT06493578 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06493578 about?
NCT06493578 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
What is the current status of trial NCT06493578?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-06-04. Estimated completion is 2026-01-30.
What conditions does trial NCT06493578 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT06493578?
The interventions under investigation include: VYN201 Gel (DRUG), Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT06493578?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06493578 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06493578's enrollment target sits among peer trials
200 6th of 9 higher than 3 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI